<DOC>
	<DOCNO>NCT00532298</DOCNO>
	<brief_summary>This observer blind study design compare immune response GSK Biologicals ' influenza vaccine GSK576389A administer use various presentation adult age 65 year old . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Non-Inferiority Various GSK Bio 's Influenza Vaccine Presentations Adults Aged 65 Years Over</brief_title>
	<detailed_description>The study contain 6 parallel group , stratify two age group : 65-74 year â‰¥ 75 year two influenza vaccination history : influenza vaccination last 3 season least one influenza vaccination last 3 season .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female age 65 year old time vaccination . Written inform consent obtain subject . Free acute aggravation health status establish clinical evaluation enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day prior vaccination , plan use study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol Visit 2 vaccination . Planned administration influenza vaccine study vaccine entire study period . Vaccination influenza since January 2007 ( include Northern Hemisphere NH 2006/2007 NH 2007/08 influenza vaccine ) . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior administration study vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History hypersensivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine ( ) Acute clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine clinical evaluation preexist laboratory screening test . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first administration study vaccine plan administration study . Any medical condition intramuscular injection contraindicate .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Fluarix</keyword>
	<keyword>Influenza Infection</keyword>
	<keyword>GSK Biologicals ' influenza vaccine GSK576389A</keyword>
</DOC>